Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
The primary study objective is to evaluate the clinical efficacy of intracranial administration of SB623 cells, using the Fugi-Meyer Motor Score (FMMS) as the primary endpoint measure. Stroke is a major cause of prolonged neurological disability in adults with an economic burden of over $62 billion in the US. Of those who experience ischemic stroke, approximately one quarter will not survive. Of the survivors, more than a third will remain functionally dependent due to their physical and
Who may be Eligible  
Patients 6 months post stroke with hemiparesis; Severe motor disability; Surgical intervention for ischemic stroke, chronic and acute; DNA modified cells to treat hemiplegia from ischemic stroke.
IRB Number  
Principal Investigator  
Nguyen, Vu Q.C.
Contact Name  

For More Information, Contact  Marybeth  , Whitney
Phone:  (704) 355-1409  Fax:  (704) 355-3676  
Email:  marybethwhitney@carolinashealthcare.org
Address:Carolinas Rehabilitation, PM&R 1100 Blythe Blvd. Charlotte, NC 28203